3 June 2024
CRISM Therapeutics Corporation
(AIM:CRTX)
Director Dealing
CRISM Therapeutics Corporation ("CRISM" or the "Company") announces that it has been notified that Non-Executive Director, Gerald Beaney has purchased 25,000 ordinary shares of the Company at a price of 9.265 pence per share.
Following this purchase, Mr Beaney holds 25,000 ordinary shares, which represents approximately 0.08% of the Company's total issued share capital of 32,678,312.
Enquiries:
| Company | Nomad and Broker | Financial PR |
| CRISM Therapeutics Corporation | S.P. Angel Corporate Finance LLP | Buchanan |
| Andrew Webb, CEO Chris McConville, CSO | Richard Morrison Adam Cowl |
Mark Court mark.court@buchanancomms.co.uk Jamie Hooper jamie.hooper@buchanancomms.co.uk |
| via Buchanan | +44 (0) 20 3470 0470 | +44 (0) 20 7466 5000 |
Dealings by Persons Discharging Managerial Responsibilities
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||||||||
| a)
| Name | Gerald Beaney | |||||||||
| 2
| Reason for the notification
| ||||||||||
| a)
| Position/status | Non-Executive Director | |||||||||
| b)
| Initial notification /Amendment | Initial Notification | |||||||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||
| a)
| Name | CRISM Therapeutics Corporation | |||||||||
| b)
| LEI
| 213800XFW6MKVCHHPW88
| |||||||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||||
| a)
| Description of the financial instrument, type of instrument | Ordinary shares with no par value | |||||||||
| | | ||||||||||
| Identification code | ISIN: VGG042401262
| ||||||||||
| | | ||||||||||
| b)
| Nature of the transaction
| Purchase of shares | |||||||||
| c)
| Price(s) and volume(s) |
|
|
|
| ||||||
| d)
| Aggregated information | | |||||||||
| | | ||||||||||
| - Aggregated volume | 25,000 | ||||||||||
| | | ||||||||||
| - Price | £2,316.25 | ||||||||||
| | | ||||||||||
| e)
| Date of the transaction | 3 June 2024 | |||||||||
| f)
| Place of the transaction | Outside a trading venue | |||||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.